Fluoroquinolone is an important class of antibiotic with a broad spectrum of activity against Gram-positive, Gramnegative and mycobacterial organisms as well as anaerobes. Particularly, moxifloxacin and gatifloxacin, fluoroquinolone antibiotics in the fourth generation, are under clinical phase for the treatment of multidrug resistant tuberculosis MDR-TB. In this paper, the authors reported the synthesis of fluoroquinolone core, the key intermediate in the synthesis of moxifloxacin and gatifloxacin.